The stock price of Myriad Genetics, Inc (NASDAQ: MYGN) has jumped by 8.37 compared to previous close of 13.09. Despite this, the company has seen a gain of 11.43% in its stock price over the last five trading days. zacks.com reported 2025-02-11 that Myriad Genetics entered into an agreement with CancerCARE for Life to provide individuals within the latter’s network with access to the MyRisk Hereditary Cancer Test.
Is It Worth Investing in Myriad Genetics, Inc (NASDAQ: MYGN) Right Now?
Moreover, the 36-month beta value for MYGN is 1.77. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 4 as “overweight,” 6 as “hold,” and 1 as “sell.”
The public float for MYGN is 87.64M and currently, short sellers hold a 5.55% of that float. On February 13, 2025, MYGN’s average trading volume was 1.03M shares.
MYGN’s Market Performance
The stock of Myriad Genetics, Inc (MYGN) has seen a 11.43% increase in the past week, with a 3.69% rise in the past month, and a -18.05% fall in the past quarter. The volatility ratio for the week is 3.74%, and the volatility levels for the past 30 days are at 5.40% for MYGN. The simple moving average for the past 20 days is 11.49% for MYGN’s stock, with a -33.82% simple moving average for the past 200 days.
Analysts’ Opinion of MYGN
Many brokerage firms have already submitted their reports for MYGN stocks, with Craig Hallum repeating the rating for MYGN by listing it as a “Buy.” The predicted price for MYGN in the upcoming period, according to Craig Hallum is $29 based on the research report published on February 12, 2025 of the current year 2025.
UBS, on the other hand, stated in their research note that they expect to see MYGN reach a price target of $18. The rating they have provided for MYGN stocks is “Neutral” according to the report published on December 10th, 2024.
Leerink Partners gave a rating of “Market Perform” to MYGN, setting the target price at $21 in the report published on December 09th of the previous year.
MYGN Trading at 3.62% from the 50-Day Moving Average
After a stumble in the market that brought MYGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.59% of loss for the given period.
Volatility was left at 5.40%, however, over the last 30 days, the volatility rate increased by 3.74%, as shares surge +7.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.91% lower at present.
During the last 5 trading sessions, MYGN rose by +11.31%, which changed the moving average for the period of 200-days by -22.06% in comparison to the 20-day moving average, which settled at $12.72. In addition, Myriad Genetics, Inc saw 3.46% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MYGN starting from DIAZ PAUL J, who sale 15,000 shares at the price of $22.93 back on Oct 11 ’24. After this action, DIAZ PAUL J now owns 962,378 shares of Myriad Genetics, Inc, valued at $343,950 using the latest closing price.
DIAZ PAUL J, the Officer of Myriad Genetics, Inc, proposed sale 15,000 shares at $22.93 during a trade that took place back on Oct 11 ’24, which means that DIAZ PAUL J is holding shares at $343,950 based on the most recent closing price.
Stock Fundamentals for MYGN
Current profitability levels for the company are sitting at:
- -0.14 for the present operating margin
- 0.69 for the gross margin
The net margin for Myriad Genetics, Inc stands at -0.14. The total capital return value is set at -0.12. Equity return is now at value -16.39, with -10.40 for asset returns.
Based on Myriad Genetics, Inc (MYGN), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -0.49. The debt to equity ratio resting at 0.2. The interest coverage ratio of the stock is -38.6.
Currently, EBITDA for the company is -186.1 million with net debt to EBITDA at -0.87. When we switch over and look at the enterprise to sales, we see a ratio of 1.63. The receivables turnover for the company is 6.55for trailing twelve months and the total asset turnover is 0.76. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.90.
Conclusion
To wrap up, the performance of Myriad Genetics, Inc (MYGN) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
